Achieved Regulatory Milestones for the MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Development Program: U.S. Food and Drug Administration (FDA) filed the Biologics License Application (BLA) Priority Review granted, Prescription Drug User Fee Act (PDUFA) date set for August 22, 2026 FDA indicated an Advisory Committee is not planned for the BLA Submitted Marketing Authorization Applications (MAAs) to the European Medicines Agency (EMA) and the U.K. Medicines and Healt

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients Single apheresis yields up to 5 billion (5×10 9 ) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxic

Utility-scale quantum computers are expected to enable chemically accurate molecular simulations with efficiency. Credit: Gorodenkoff / Shutterstock.com. PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing within drug discovery and oncology. The partnership aims to investigate ways to implement quantum computing solutions throughout the healthcare value chain, with a focus on resource allocation,

Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a cr

SINGAPORE, 13 March 2026 — Precision oncology firm, Lucence, with Diagnostics Development Hub (DxD Hub), hosted by the Agency for Science, Technology and Research (A*STAR), Singapore and the National Cancer Centre Singapore (NCCS), officially launched UNITED 2.0, a S$6 million research collaboration to develop a next-generation, clinical grade cancer profiling test with the goal of advancing the future of precision diagnostics. The collaboration builds on the original UNITED 1.0 tissue test, als

STOCKHOLM, SE / ACCESS Newswire / March 12, 2026 / iZafe Group (STO:IZAFE-B) - An Extraordinary General Meeting was held in iZafe Group AB, reg. no. 556762-3391 (the "Company"), on 12 March 2026 at the Company's office. The Extraordinary General Meeting resolved to approve the Board of Directors' resolution of 19 February 2026 regarding a directed issue of up to 39,236,014 class B shares. The directed share issue constitutes the second part of the capital raise that was announced through a pr

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026 Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph

Researchers studying over 8,400 colonoscopies discovered that having both adenomas and serrated polyps in the bowel can raise the risk of serious precancerous changes by up to five times. These two polyp types may represent separate cancer pathways that can occur at the same time. Nearly half of patients with serrated polyps also had adenomas, making this high-risk combination more common than expected. The results emphasize the importance of early detection and regular colonoscopy monitoring.Re

iStock, Nuthawut Somsuk Dozens of biotechs reported earnings this week. BioSpace recaps key highlights from Capricor Therapeutics, Legend Biotech, Inovio and Allogene. Myriad biotechs reported earnings this week, with stories ranging from Legend Biotech’s near-term goal of hitting profitability this year to Capricor Therapeutics’ regulatory comeback. 2025 was a rollercoaster year for biotech as regulatory uncertainty and a policy focus on drug pricing sent the markets into tumult. While a com

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Dr